Emblem Receives Health Canada License to Sell Cannabis Extracts
TORONTO, Nov. 06, 2017 (GLOBE NEWSWIRE) — Emblem Corp. (“Emblem” or the “Company”) (TSX-V:EMC), a vertically integrated health and wellness company focused on research, development, production and distribution of cannabis products for medical and pharmaceutical purposes, is pleased to announced that, effective November 3, 2017, the Company has been granted a license to sell cannabis oils. As announced on December 19, 2016, Emblem was initially granted a supplemental license for the production of cannabis extracts.
Securing this license is an important milestone of our strategy to provide high quality, differentiated cannabis products, in a variety of formats. Our clients will be able to rely upon a selection of cannabis oils, including those from CBD dominant strains, THC dominant strains and strains with both CBD and THC content. Cannabis oils and related formulations provide a level of consistency and dosage accuracy that cannot be achieved with dried flower, and is a substantially more convenient and precise consumption method.
John H. Stewart, President of Emblem’s Pharmaceutical Division
We are very excited with the prospects this license brings, as we continue our clinical R&D initiatives towards unique cannabinoid delivery formulations, which we intend to introduce to the market in the future.
Emblem anticipates announcing its updated product portfolio later this month, based on the addition of a range of cannabis oils, and commencing sales of its full product line shortly thereafter.
About Emblem
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical cannabis. Emblem carries out its principal activities producing cannabis from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.
